#	Pagina
attuale pagina	/open-h2020/projects/197308/index.html

Opendata, web and dolomites

VALID-SCREEN SIGNED

Validation of PreCursor-M for enhanced Cervical (Pre)Cancer detection

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

VALID-SCREEN project word cloud

Explore the words cloud of the VALID-SCREEN project. It provides you a very rough idea of what is the project "VALID-SCREEN" about.

alone countries preventable 2012 drawback risk infection cancer centres precursor assay replace marker overtreatment overdiagnosis settings with seventh disease hrhpv panel ed tests combined found primary 266 mir124 cc valid proportional severity characterised separately self decrease clinical identification complete markers specificity causing deaths shown final supplementing triage fourth cervical regular cadm1 cells commercial incidence marked host screening cohorts multiplex progression molecular validated follow screen small validation cytology curable laboratory biomarkers methylation proprietary 528 stand mal sustainable place dna women

Project "VALID-SCREEN" data sheet

The following table provides information about the project.

Coordinator	SELF-SCREEN BV Organization address address: BIOTHOF 15 1 city: AMSTERDAM postcode: 1098 RX website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Netherlands [NL]
Project website	http://www.self-screen.nl/index.php
Total cost	3˙264˙375 €
EC max contribution	3˙264˙375 € (100%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-SMEINST-2-2014
Funding Scheme	SME-2
Starting year	2015
Duration (year-month-day)	from 2015-07-01 to 2019-03-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	SELF-SCREEN BV SELF-SCREEN BV Organization address address: BIOTHOF 15 1 city: AMSTERDAM postcode: 1098 RX website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (AMSTERDAM)	coordinator	3˙264˙375.00

Map

Project objective

With an estimated 528,000 new cases and 266,000 deaths in 2012, cervical cancer (CC) is the fourth most common type of cancer in women, and the seventh overall. CC is preventable with regular screening tests and follow-up, and curable if found and treated early. In many countries, screening programmes for cervical cancer are in place, which have resulted in a marked decrease in cervical cancer incidence. hrHPV DNA testing will replace cytology as primary screening test for CC, but its drawback as stand-alone CC screening test is its low specificity, causing overdiagnosis and overtreatment. Triage of hrHPV women is essential to maintain a sustainable screening programme. PreCursor-M (Self-screen B.V.) is a proprietary molecular assay to determine disease progression and severity based on the methylation level of 3 host-biomarkers. Supplementing hrHPV DNA screening with PreCursor-M will provide information on the presence of infection, and the response by the host cells. This will allow identification of all women at risk for cervical cancer without overdiagnosis and overtreatment. The methylation level of three molecular markers (CADM1, MAL and miR124-2) was shown to increase proportional to cervical cancer progression and severity. In Precursor-M, these markers have been combined in a multiplex methylation marker panel. The markers have been separately validated in clinical settings, and the combined marker panel has been validated in laboratory and small-scale clinical settings. VALID-SCREEN will complete the final step towards commercial success for PreCursor-M: clinical validation of PreCursor-M in well-characterised cohorts, from five clinical centres, in four EU countries, as a triage test to hrHPV screening for cervical cancer.

Deliverables

List of deliverables.
Communication plan	Websites, patent fillings, videos etc.	2019-05-30 12:47:15
Data Managment PLan	Websites, patent fillings, videos etc.	2019-05-30 11:25:30

Take a look to the deliverables list in detail: detailed list of VALID-SCREEN deliverables.

Publications

List of publications.
year	authors and title	journal	last update
2018	Arno Floore, Albertus Hesselink, Anja OÅ¡trbenk, Elia Alcaniz, Beate Rothe, Helle Pedersen, Montserrat Torres Hortal, Saskia Doorn, Wim Quint, Karl Ulrich Petry, Mario Poljak, Kate Cuschieri, Jesper Bonde, Silvia de SanjosÃ©, Maaike Bleeker, DaniÃ«lle Heideman Intra- and inter-laboratory agreement of the FAM19A4/mir124-2 methylation test: Results from an international study published pages: e22854, ISSN: 0887-8013, DOI: 10.1002/jcla.22854	Journal of Clinical Laboratory Analysis	2019-04-13
2016	Roosmarijn Luttmer, Lise M. A. De Strooper, Renske D. M. Steenbergen, Johannes Berkhof, Peter J. F. Snijders, DaniÃ«lle A. M. Heideman, Chris J. L. M. Meijer Management of high-risk HPV-positive women for detection of cervical (pre)cancer published pages: 1-14, ISSN: 1473-7159, DOI: 10.1080/14737159.2016.1217157	Expert Review of Molecular Diagnostics	2019-08-30

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "VALID-SCREEN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "VALID-SCREEN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

RESHAPE (2019)

Reshaping undesired Inflammation in challenged Tissue Homeostasis by Next-Generation regulatory T cell (Treg) Approaches – from Advanced Technology Developments to First-in-Human Trials

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

DIAdIC (2019)

Evaluation of Dyadic Psychoeducational Interventions for People with Advanced Cancer and their Informal Caregivers (DIAdIC): An international randomized controlled trial